Randomized control trial of nitazoxanide for the treatment of cryptosporidium infection in malnourished children in bangladesh
Active Cooperative Agreement Awarded Last action
- Award ID
- U01AI167788
- Recipient
-
The Johns Hopkins University UEI FTMTDMBR29C7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,984,497
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 70% complete
- Place of performance
- Baltimore, MD 21205, USA
Award details come from USAspending.gov.
Description
- Abstract
- Cryptosporidiosis is a leading contributor to child morbidity and mortality worldwide, responsible for over 200,000 deaths in children under two, and morbidity in over 7 million children. However, we have limited treatment and no vaccine for use in young children. Our prior work in bangladesh has demonstrated that almost 80% of children in an urban slum cohort were infected with cryptosporidium SPP. By age two and that infection, even without diarrhea, was significantly associated with long-term growth faltering. Nitazoxanide is the only FDA-approved drug for treatment of cryptosporidium diarrheal disease. However, the drug has limited widespread due to lack of large-scale, unbiased rigorous trials demonstrating its efficacy in children under one and establishing its safety in this population. Furthermore, little is known about how the drug could treat non-diarrheal infection and alleviate cryptosporidium's effect on child growth. Here we propose a double-blind, randomized, placebo-controlled trial aimed at treating children ages 6-12 months with cryptosporidium-diarrheal and non-diarrheal infection. The study will evaluate the efficacy of treatment for both conditions and will also evaluate whether treatment can improve growth in children for 6 months post-treatment. This proposal leverages a longstanding collaboration between johns hopkins university and the international centre for diarrhoeal disease, research, bangladesh. This proposal is innovative, as IT will be the first randomized controlled trial aimed at treatment of non-diarrheal cryptosporidium infection and will evaluate impact on growth. The findings from this study will inform treatment efforts aid to protect young children from this devastating infectious disease.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $258,400 | |
| Amendment | $378,055 | |
| Amendment | $378,055 | |
| Amendment | $196,370 | |
| Amendment | $500,492 | |
| Amendment | $718,217 | |
| Amendment | $777,454 | |
| Original award | $777,454 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| International Centre For Diarrhoeal Disease Research, Bangladesh | $404,670 | |
| International Centre For Diarrhoeal Disease Research, Bangladesh | $194,032 |
Quick answers
Who received award U01AI167788?
U01AI167788 was awarded to The Johns Hopkins University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 22, 2023.
How much is award U01AI167788 worth?
$3,984,497 has been obligated on U01AI167788.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award